CSIMarket
 


Avidity Biosciences Inc   (RNA)
Other Ticker:  
 

Avidity Biosciences Inc 's Total Debt to Equity

RNA's quarterly Total Debt to Equity and Total Debt, Equity growth


In the forth quarter 2023 Avidity Biosciences Inc did not have Total Debt.

Within Major Pharmaceutical Preparations industry Avidity Biosciences Inc achieved the lowest Total Debt to Equity in the forth quarter 2023. While total ranking remained the same in the forth quarter 2023 compared to the previous quarter at no. .

Explain Debt to Equity Ratio?
What is the structure of RNA´s Total Debt?
How valuable is the RNA´s Equity?


RNA Total Debt to Equity (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -13.37 % 37.27 % 49.37 % 48.76 % 51.55 %
Y / Y Total Debt Change - - - - -
Total Debt to Equity MRQ - - - - -
RNA's Total Ranking # # # # #
Seq. Equity Change -3.23 % -7.46 % 0.05 % -3.31 % 53.34 %
Seq. Total Debt Change - - - - -



Total Debt to Equity forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Total Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Avidity Biosciences Inc 's Equity $ 501 Millions Visit RNA's Balance sheet
Avidity Biosciences Inc 's Total Debt $ 0 Millions Visit RNA's Balance sheet
Source of RNA's Sales Visit RNA's Sales by Geography


Cumulative Avidity Biosciences Inc 's Total Debt to Equity

RNA's Total Debt to Equity for the trailling 12 Months

RNA Total Debt to Equity

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -13.37 % 37.27 % 49.37 % 48.76 % 51.55 %
Y / Y Total Debt TTM Growth - - - - -
Total Debt to Equity TTM - - - - -
Total Ranking TTM
Seq. Equity TTM Growth -3.23 % -7.46 % 0.05 % -3.31 % 53.34 %
Seq. Total Debt TTM Growth - - - - -


On the trailing twelve months basis During the twelve months ending IV Quarter 2023 Avidity Biosciences Inc did not have Total Debt .
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry RNA recorded the lowest Total Debt to Equity. While total ranking remained unchanged compared to previous 12 month period at no. 0.

Explain Debt to Equity Ratio?
What is the structure of RNA´s Total Debt?
How valuable is the RNA´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Within the Market #


trailing twelve months Total Debt to Equity Statistics
High Average Low
0 0 0
 




Companies with similar Total Debt to Equity in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Total Debt to EquityDec 31 2023 MRQ Total DebtDec 31 2023 MRQ Equity

Date modified: 2024-02-29T16:08:01+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com